Flt3 (phospho Tyr599) rabbit pAb

SKU: ES5320

Size: 100μL

Source:Rabbit

Applications:WB;ELISA

Reactivity:Human;Mouse;Monkey

Dilution:Western Blot: 1/500 - 1/2000. ELISA: 1/5000. Not yet tested in other applications.

Immunogen:The antiserum was produced against synthesized peptide derived from human FLT3 around the phosphorylation site of Tyr599. AA range:565-614

Storage_stability:-20°C/1 year

Clonality:Polyclonal

Isotype:IgG

Concentration:1 mg/ml

Observed_band(KD):160kD

Human_gene_id:2322

Human_swiss_prot_no:P36888

Subcellular_location:Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen. Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation.

Other_name:FLT3; CD135; FLK2; STK1; Receptor-type tyrosine-protein kinase FLT3; FL cytokine receptor; Fetal liver kinase-2; FLK-2; Fms-like tyrosine kinase 3; FLT-3; Stem cell tyrosine kinase 1; STK-1; CD antigen CD135

Background:This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. [provided by RefSeq, Jan 2015],